Esomeprazole News and Research

RSS
Esomeprazole is a drug that blocks acid from being made in the stomach. It is used to treat acid reflux disease and to prevent certain types of gastrointestinal ulcers. Esomeprazole magnesium is being studied in the prevention of esophageal cancer and in the treatment of other conditions, including side effects of chemotherapy. It is a type of anti-ulcer agent. Also called esomeprazole and Nexium.
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN reports total revenue of $4.7 million for fourth quarter 2013

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Brazilian study provides evidence to support effectiveness of Tecta in erosive GERD

Brazilian study provides evidence to support effectiveness of Tecta in erosive GERD

Pfizer's Polish subsidiary acquires rights to Polocard from ZF Polpharma SA

Pfizer's Polish subsidiary acquires rights to Polocard from ZF Polpharma SA

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck announces approval of NOXAFIL delayed-release tablets by FDA

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

POZEN announces revenue of $1.4 million for first quarter 2013

POZEN announces revenue of $1.4 million for first quarter 2013

FDA accepts Merck's NDA for NOXAFIL tablets

FDA accepts Merck's NDA for NOXAFIL tablets

Amneal enters license and distribution agreement with Hanmi for generic Nexium

Amneal enters license and distribution agreement with Hanmi for generic Nexium

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

AstraZeneca enters agreement with Pfizer for OTC NEXIUM

AstraZeneca enters agreement with Pfizer for OTC NEXIUM

Three U.S. Army medical residents earn national awards at ACP annual meeting

Three U.S. Army medical residents earn national awards at ACP annual meeting

Multiple companies receive FDA approval to sell generic Plavix

Multiple companies receive FDA approval to sell generic Plavix

C&EN explains logic behind odd-sounding generic names

C&EN explains logic behind odd-sounding generic names

POZEN third quarter revenue increases to $4.9 million

POZEN third quarter revenue increases to $4.9 million

AstraZeneca Canada introduces new NEXIUM Patient Support program

AstraZeneca Canada introduces new NEXIUM Patient Support program